tezepelumab (Tezspire)

following a full submission:

tezepelumab (Tezspire®) is accepted for restricted use within NHSScotland.

Indication under review: as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

SMC restriction: in adults and adolescents 12 years and older who either (i) experienced at least three exacerbations in the previous year and are not receiving maintenance treatment with oral corticosteroids or (ii) have blood eosinophils ≥150 cells/microlitre and are receiving maintenance treatment with oral corticosteroids.

Compared with placebo, the addition of tezepelumab to inhaled corticosteroids and at least one additional controller medicine, significantly reduced the annual asthma exacerbation rate in patients with inadequately controlled severe asthma.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.